Retinoblastoma is a rare cancer of the retina of the eye. Learn more about this condition in children.
Children’s National Hospital has a team of individuals who are highly skilled and experienced in the treatment of bone tumors, including osteosarcoma and Ewing sarcoma. Learn more about these conditions.
Leukemia is cancer of the blood. It's the most common kind of cancer in children. Learn more about this condition and the treatments we offer.
Rhabdomyosarcoma is a rare type of cancer that starts in the cells that develop into skeletal muscle cells. Learn more about this condition and the treatments we offer.
Soft tissue sarcoma is a type of cancer that grows in soft tissues that support and connect parts of the body.
Germ cell tumors are tumors that are comprised mostly of germ cells. Germ cells are the cells that develop and become the cells that make up the reproductive system. Learn more about this condition.
Non-Hodgkin lymphoma is cancer in the lymphatic system. The lymphatic system is part of the immune system and functions to fight disease and infections. Learn more about its causes and treatments.
Nasopharyngeal carcinoma is a rare type of cancer that occurs in the nasal cavity and the pharynx, the upper part of the throat behind the nose. Learn more about its causes and treatments.
Pediatric neuroblastoma is a cancerous tumor that begins in nerve tissue of infants and very young children.
A brain tumor is an abnormal growth of tissue in the brain or spinal cord. Learn more about this condition.
Learn more about our collaborative Pediatric Radiation Oncology Program, which focuses on advancing pediatric clinical care and pediatric radiation oncology research.
We deliver comprehensive care for all blood cancers including chemotherapy, bone marrow transplant and experimental therapeutics.
Our Solid Tumor Program has a dedicated team of sarcoma experts who specialize in the newest treatments and clinical trials.
Our oncology (cancer) team provides personalized treatment plans for children with cancer, including access to clinical trials.